CAJ | 학술논문

目的：运用Meta分析研究以卡培他滨为基准的新辅助化疗方案与进展期胃癌患者生存率、根治性手术切除率、总手术率的关系，为进展期胃癌的临床治疗提供统计学证据。方法以网上检索Pubmed、Medline、Embase、Cochrane等数据库，同时手工检索相关会议论文集、学位论文汇编等，检索年限从建库至2014年10月。检索进展期胃癌行以含卡培他滨为基准的新辅助化疗方案化疗有关的临床对照试验。按照纳入和排除标准对文献进行筛选，再进行质量评价，运用Cochrane协作网站提供的RevMan5.2统计学软件对所提取的数据进行Mate分析。结果共纳入8个随机对照试验。其中中文文献7篇，英文文献1篇，共有699例患者入选，实验组351例，对照组348例。Meta分析结果显示，含卡培他滨的新辅助化疗组与不含卡培他滨的新辅助化疗组和单纯手术组比较1年生存率、根治性手术切除率(R0)、总手术率(R1)差异有统计学意义(P＜0.05)，其OR值和95% CI分别为2.97(1.79~4.91)、2.94(2.03~4.26)、3.54(2.31~5.43)。结论含卡培他滨的新辅助化疗组和不含卡培他滨的新辅助化疗组及单纯手术组相比，能提高进展期胃癌患者的1年生存率、根治性手术切除率(R0)和总手术率(R1)。
목적：운용Meta분석연구이잡배타빈위기준적신보조화료방안여진전기위암환자생존솔、근치성수술절제솔、총수술솔적관계，위진전기위암적림상치료제공통계학증거。방법이망상검색Pubmed、Medline、Embase、Cochrane등수거고，동시수공검색상관회의논문집、학위논문회편등，검색년한종건고지2014년10월。검색진전기위암행이함잡배타빈위기준적신보조화료방안화료유관적림상대조시험。안조납입화배제표준대문헌진행사선，재진행질량평개，운용Cochrane협작망참제공적RevMan5.2통계학연건대소제취적수거진행Mate분석。결과공납입8개수궤대조시험。기중중문문헌7편，영문문헌1편，공유699례환자입선，실험조351례，대조조348례。Meta분석결과현시，함잡배타빈적신보조화료조여불함잡배타빈적신보조화료조화단순수술조비교1년생존솔、근치성수술절제솔(R0)、총수술솔(R1)차이유통계학의의(P＜0.05)，기OR치화95% CI분별위2.97(1.79~4.91)、2.94(2.03~4.26)、3.54(2.31~5.43)。결론함잡배타빈적신보조화료조화불함잡배타빈적신보조화료조급단순수술조상비，능제고진전기위암환자적1년생존솔、근치성수술절제솔(R0)화총수술솔(R1)。
Objective To study the curative effect of neoadjuvant chemotherapy with capecitabine as a benchmark for treating advanced gastric cancer by performing a meta-analysis of the published studies, then provide statistical evidence for the clinical treatment of advanced gastric cancer.Methods The database of Pubmed, CBMdisc, Embase and Cochrane aided with manual retrieval and other retrievals were searched to screen neoadjuvant chemotherapy containing capecitabine in the treatment of advanced gastric cancer in randomized controlled trials (RCT). The RevMan5.2 software was used for meta-analysis after extracting the useful data.Results Eight randomized controlled trials involved a total of 699 patients with advanced gastric cancer were studied. Of the 8 trials, 7 were published by Chinese, 1 were published by English. Of the 699 patients, 351 were treated by neoadjuvant chemotherapy containing capecitabine, 348 were treated by neoadjuvant chemotherapy excluding capecitabine or without treating by neoadjuvant chemotherapy. According to the meta-analysis of the available information, there were statistical differences in 1-year survival rate, radical operation resection rate (RO), total operation rate (R1) (P<0.05). TheOR rate and 95% CI were 2.97 (1.79-4.91) for 1-year survival rate, 2.94 (2.03-4.26) for RO and 3.54 (2.31-5.43) for R1.Conclusion Compared with neoadjuvant chemotherapy excluding capecitabine or patients without neoadjuvant chemotherapy, neoadjuvant chemotherapy containing capecitabine can improve the 1-year survival rate, radical operation resection rate and total operation rate in patients with advanced gastric cancer.